Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-088131 · Präparat HOS-083615
CONTRACEPTIVES
Depo- DMPA AUC Viramune co-administration did
medroxyprogesterone DMPA Cmin not alter the ovulation suppression
acetate (DMPA) DMPA Cmax effects of DMPA. DMPA and
150 mg every 3 months Viramune can be co-administered
Nevirapine AUC 1.20 without dose adjustments.
Nevirapine Cmax 1.20
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) medroxyprogesterone (HOS-088132)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 1e2ba6e66ad3a032540fbef8e974948601df023c6bb7c5bc71cf1706bfd85ab2 · Zeichen 22073–22591 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 39
HOS-088226 · Präparat HOS-083615
CONTRACEPTIVES
Depo- DMPA AUC Viramune co-administration did
medroxyprogesterone DMPA Cmin not alter the ovulation suppression
acetate (DMPA) DMPA Cmax effects of DMPA. DMPA and
150 mg every 3 months Viramune can be co-administered
Nevirapine AUC 1.20 without dose adjustments.
Nevirapine Cmax 1.20
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) medroxyprogesterone (HOS-088132)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 1e2ba6e66ad3a032540fbef8e974948601df023c6bb7c5bc71cf1706bfd85ab2 · Zeichen 22213–22731 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 65
HOS-088316 · Präparat HOS-083615
CONTRACEPTIVES
Depo- DMPA AUC Viramune co-administration did
medroxyprogesterone DMPA Cmin not alter the ovulation suppression
acetate (DMPA) DMPA Cmax effects of DMPA. DMPA and
150 mg every 3 months Viramune can be co-administered
Nevirapine AUC 1.20 without dose adjustments.
Nevirapine Cmax 1.20
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) medroxyprogesterone (HOS-088132)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage a6b848de4112ed120418c06cd8129c1368080fba208b5a3fe464b39ea1589d49 · Zeichen 22272–22785 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 200 mg tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-120825 · Präparat HOS-095225
5
exposure to carbamazepine or its metabolite carbamazepine-epoxide was noted. Based on individual
response, the dose of eslicarbazepine acetate may need to be increased if used concomitantly with
carbamazepine. Results from patient studies showed that concomitant treatment increased the risk of
the following adverse reactions: diplopia, abnormal coordination and dizziness. The risk of increase of
other specific adverse reactions caused by co-administration of carbamazepine and eslicarbazepine
acetate cannot be excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) carbamazepine (HOS-085618)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage cdb4ce1bb885d1b609bab6c29d9e66cd663d63957928d386d99a1940f2709dd5 · Zeichen 1776–2303 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 400 mg tablets · Abschnitt 4.5 · PDF-Seite 23–24
HOS-120870 · Präparat HOS-095225
23
In a study in healthy subjects, concomitant administration of eslicarbazepine acetate 800 mg once
daily and carbamazepine 400 mg twice daily resulted in an average decrease of 32% in exposure to the
active metabolite eslicarbazepine, most likely caused by an induction of glucuronidation. No change in
exposure to carbamazepine or its metabolite carbamazepine-epoxide was noted. Based on individual
response, the dose of eslicarbazepine acetate may need to be increased if used concomitantly with
carbamazepine. Results from patient studies showed that concomitant treatment increased the risk of
the following adverse reactions: diplopia, abnormal coordination and dizziness. The risk of increase of
other specific adverse reactions caused by co-administration of carbamazepine and eslicarbazepine
acetate cannot be excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) carbamazepine (HOS-085618)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage 46a9a4ca0eb49aa8ce9271315002bc7be1ef4687ef340936094e5b90e9053821 · Zeichen 1473–2303 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 600 mg tablets · Abschnitt 4.5 · PDF-Seite 41–42
HOS-120909 · Präparat HOS-095225
Carbamazepine
In a study in healthy subjects, concomitant administration of eslicarbazepine acetate 800 mg once
daily and carbamazepine 400 mg twice daily resulted in an average decrease of 32% in exposure to the
active metabolite eslicarbazepine, most likely caused by an induction of glucuronidation. No change in
41
exposure to carbamazepine or its metabolite carbamazepine-epoxide was noted. Based on individual
response, the dose of eslicarbazepine acetate may need to be increased if used concomitantly with
carbamazepine. Results from patient studies showed that concomitant treatment increased the risk of
the following adverse reactions: diplopia, abnormal coordination and dizziness. The risk of increase of
other specific adverse reactions caused by co-administration of carbamazepine and eslicarbazepine
acetate cannot be excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) carbamazepine (HOS-085618)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage 0c8f8c9c73a8124bbdc83ce49ee684f892d472cce4c5768c4f3b5e963dc1b68f · Zeichen 1408–2302 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 800 mg tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-120950 · Präparat HOS-095225
Carbamazepine
In a study in healthy subjects, concomitant administration of eslicarbazepine acetate 800 mg once
daily and carbamazepine 400 mg twice daily resulted in an average decrease of 32% in exposure to the
active metabolite eslicarbazepine, most likely caused by an induction of glucuronidation. No change in
59
exposure to carbamazepine or its metabolite carbamazepine-epoxide was noted. Based on individual
response, the dose of eslicarbazepine acetate may need to be increased if used concomitantly with
carbamazepine. Results from patient studies showed that concomitant treatment increased the risk of
the following adverse reactions: diplopia, abnormal coordination and dizziness. The risk of increase of
other specific adverse reactions caused by co-administration of carbamazepine and eslicarbazepine
acetate cannot be excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) carbamazepine (HOS-085618)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage 93719ce1aa5748a76b0ecafa939e56eb9ede04821b6016005cdb24704144ee07 · Zeichen 1408–2302 im Abschnitt
Wechselwirkungen · Zebinix
Zebinix 50 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 77–78
HOS-120993 · Präparat HOS-095225
77
active metabolite eslicarbazepine, most likely caused by an induction of glucuronidation. No change in
exposure to carbamazepine or its metabolite carbamazepine-epoxide was noted. Based on individual
response, the dose of eslicarbazepine acetate may need to be increased if used concomitantly with
carbamazepine. Results from patient studies showed that concomitant treatment increased the risk of
the following adverse reactions: diplopia, abnormal coordination and dizziness. The risk of increase of
other specific adverse reactions caused by co-administration of carbamazepine and eslicarbazepine
acetate cannot be excluded.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) carbamazepine (HOS-085618)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage 7575cb60351ac1a54aa9c9e560834202f08b1ba27b76ae61aa0f1258fc860e48 · Zeichen 1672–2303 im Abschnitt
Wechselwirkungen · ellaOne
ellaOne 30 mg tablet · Abschnitt 4.5 · PDF-Seite 4
HOS-121386 · Präparat HOS-095343
The CYP3A4 inhibitor ritonavir can also have an inducing effect on CYP3A4 when ritonavir is
used for a longer period. In such cases ritonavir might reduce plasma concentrations of ulipristal
acetate. Concomitant use is therefore not recommended (see section 4.4). Enzyme induction
wears off slowly and effects on the plasma concentrations of ulipristal acetate may occur even if
a woman has stopped taking an enzyme inducer in the past 4 weeks.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) ulipristal acetate (HOS-121379) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-29T13:44:00Z · SHA-256 3bcc90490ab5bf0dd081a2d800bb02d498a50e916a38764a4f0fc343e4f5e8b6 · Passage 20020d6a7da9906f87694224287f84451cc9869e241f92f932e08ce046ffbb87 · Zeichen 1500–1968 im Abschnitt
Wechselwirkungen · ellaOne
ellaOne 30 mg film-coated tablet · Abschnitt 4.5 · PDF-Seite 15
HOS-121413 · Präparat HOS-095343
The CYP3A4 inhibitor ritonavir can also have an inducing effect on CYP3A4 when ritonavir is
used for a longer period. In such cases ritonavir might reduce plasma concentrations of ulipristal
acetate. Concomitant use is therefore not recommended (see section 4.4). Enzyme induction
wears off slowly and effects on the plasma concentrations of ulipristal acetate may occur even if
a woman has stopped taking an enzyme inducer in the past 4 weeks.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acetate (HOS-088133) ulipristal acetate (HOS-121379) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-29T13:44:00Z · SHA-256 3bcc90490ab5bf0dd081a2d800bb02d498a50e916a38764a4f0fc343e4f5e8b6 · Passage 20020d6a7da9906f87694224287f84451cc9869e241f92f932e08ce046ffbb87 · Zeichen 1500–1968 im Abschnitt
Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-215319 · Präparat HOS-155418
Efavirenz: no clinically significant
interaction.
The clinical significance of these
effects is not known.
Injection: In a 3-month drug interaction study, Because of the limited
Depomedroxyprogesterone no significant differences in MPA information available, a reliable
acetate (DMPA)/efavirenz pharmacokinetic parameters were method of barrier contraception
(150 mg IM single dose DMPA) found between subjects receiving must be used in addition to
efavirenz-containing antiretroviral hormonal contraceptives (see
therapy and subjects receiving no section 4.6).
antiretroviral therapy. Similar results
were found by other investigators,
although the MPA plasma levels were
more variable in the second study. In
both studies, plasma progesterone
levels for subjects receiving efavirenz
and DMPA remained low consistent
with suppression of ovulation.
Implant: Etonogestrel/efavirenz Decreased exposure of etonogestrel A reliable method of barrier
may be expected (CYP3A4 contraception must be used in
induction). There have been addition to hormonal
occasional postmarketing reports of contraceptives (see section 4.6).
contraceptive failure with
etonogestrel in efavirenz-exposed
patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) acetate (HOS-088133) etonogestrel (HOS-144596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage 8952614af172de542468d8f04a229b11865e1da72dd9cff88f789d1c400a8a34 · Zeichen 55262–57260 im Abschnitt
Wechselwirkungen · Selincro
Selincro 18 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-127547 · Präparat HOS-096425
Based on in vitro studies, no clinically relevant interactions between nalmefene, or its metabolites, and
concomitantly administered medicinal products metabolised by the most common CYP450 and UGT
enzymes or membrane transporters are anticipated. Co-administration with medicinal products that are
potent inhibitors of the UGT2B7 enzyme (for example, diclofenac, fluconazole, medroxyprogesterone
acetate, meclofenamic acid) may significantly increase the exposure to nalmefene. This is unlikely to
present a problem with occasional use, but if long-term concurrent treatment with a potent UGT2B7
inhibitor is initiated, a potential for an increase in nalmefene exposure cannot be excluded
(see section 4.4). Conversely, concomitant administration with a UGT inducer (for example,
dexamethasone, phenobarbital, rifampicin, omeprazole) may potentially lead to subtherapeutic
nalmefene plasma concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): meclofenamic acid (HOS-127550) diclofenac (HOS-085903) acetate (HOS-088133) phenobarbital (HOS-085617) nalmefene (HOS-115837) dexamethasone (HOS-084535) lead (HOS-085592) medroxyprogesterone (HOS-088132) fluconazole (HOS-087945) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-07T14:41:00Z · SHA-256 33e306a05073974202b9dcd16eeb2a7e14ad94d43e4edbbf04adc0b88df7e8a1 · Passage f4955a4d19632a870b602e2f1608f5fccd1b9a74fd877ed6f9cb03c3731a9040 · Zeichen 63–969 im Abschnitt
Wechselwirkungen · Akeega
Akeega 50 mg/500 mg film-coated tablets Akeega 100 mg/500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-150305 · Präparat HOS-100288
Effects of other medicinal products on niraparib or abiraterone acetate
CYP3A4 inducers and inhibitors
Abiraterone is a CYP3A4 substrate. In a clinical study in healthy subjects pretreated with the strong
CYP3A4 inducer rifampicin, 600 mg daily for six days, followed by a single dose of abiraterone
acetate 1 000 mg, the mean plasma AUC∞ of abiraterone was decreased by 55%. Strong inducers of
CYP3A4 (e.g., phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarbital, St. John’s
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): niraparib (HOS-136825) acetate (HOS-088133) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) rifapentine (HOS-116386) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T15:30:00Z · SHA-256 1bec7f3e5f18e4fe578c0f49b6a9128776963f703a1a9503180dea643f434459 · Passage 5a39257e1810acd5e43bc7e19d038bcfdd51d101b51ec7daeaa4dc3afba10b0b · Zeichen 287–783 im Abschnitt
Wechselwirkungen · Akeega
Akeega 50 mg/500 mg film-coated tablets Akeega 100 mg/500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-150309 · Präparat HOS-100288
Effects of niraparib or abiraterone acetate on other medicinal products
CYP2D6 substrates
Abiraterone is an inhibitor of CYP2D6. In a clinical study to determine the effects of abiraterone
acetate plus prednisone (AAP) on a single dose of the CYP2D6 substrate dextromethorphan, the
systemic exposure (AUC) of dextromethorphan was increased approximately 2.9-fold. The AUC24 for
dextrorphan, the active metabolite of dextromethorphan, increased approximately 33%. Dose
reduction of medicinal products with a narrow therapeutic index that are metabolised by CYP2D6
should be considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol,
propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine,
oxycodone and tramadol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): niraparib (HOS-136825) propafenone (HOS-084530) codeine (HOS-090544) acetate (HOS-088133) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) dextromethorphan (HOS-109265) prednisone (HOS-084526) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T15:30:00Z · SHA-256 1bec7f3e5f18e4fe578c0f49b6a9128776963f703a1a9503180dea643f434459 · Passage 704800110d63379fb341b1ca9221e58b93483aec5c2142b646bcbfc2ed920ac5 · Zeichen 1171–1951 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.